Planas A, Simo-Servat O, Hernandez C, Ortiz-Zuniga A, Marsal JR, Herance JR, Ferreira-Gonzalez I, Simo R. Diabetic retinopathy and skin tissue advanced glycation end products are biomarkers of cardiovascular events in type 2 diabetic patients. J Pers Med. 2021 Dec 10;11(12):1344.
Brunette CA, Dong OM, Vassy JL, Danowski ME, Alexander N, Antwi AA, Christensen KD. A cost–consequence analysis of preemptive SLCO1B1 testing for statin myopathy risk compared to usual care. J Pers Med. 2021 Oct 31;11(11):1123. doi: 10.3390/jpm11111123
Sperber NR, Dong OM, Roberts MC, Dexter P, Elsey AR, Ginsburg GS, Horowitz CR, Johnson JA, Levy KD, Ong H, Peterson JF, Pollin TI, Rakhra-Burris T, Ramos MA, Skaar T, Orlando LA. Strategies to integrate genomic medicine into clinical care: evidence from the IGNITE network. J Pers Med. 2021 Jul 8;11(7):647. doi: 10.3390/jpm11070647
Rodriguez-Salas N, Dominguez G, Barderas R, Mendiola M, Garcia-Albeniz X, Maurel J, Batlle JF. Clinical relevance of colorectal cancer molecular subtypes. Crit Rev Oncol Hematol. 2017 Jan;109:9-19. doi: 10.1016/j.critrevonc.2016.11.007
Fernandez MM, Wang J, Ye X, Kwong WJ, Sherif B, Hogue S, Sherrill B. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score slanted greater than or equal to 2. SAGE Open Med. 2015 Dec. doi: 10.1177/2050312115613350
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.